

## PRODUCT:

**LOXO-195**

## ALTERNATE NAME:

(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one


## CATALOG #:

B2226-1,5

## AMOUNT:

1 mg, 5 mg

## STRUCTURE:



## MOLECULAR FORMULA:

C<sub>20</sub>H<sub>21</sub>FN<sub>6</sub>O

## MOLECULAR WEIGHT:

380.43

## CAS NUMBER:

2097002-61-2

## APPEARANCE:

Crystalline solid

## SOLUBILITY:

DMSO

## PURITY:

≥98% by HPLC

## STORAGE:

Store at -20 °C. Protect from light and light

## DESCRIPTION:

LOXO-195 is a potent and selective TRK (tropomyosin-related-kinase) inhibitor, with potential anticancer activity. LOXO-195 specifically targets and binds to TRK, including the fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1), 2 (NTRK2), and 3 (NTRK3). This prevents neurotrophin-TRK interaction and TRK activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins.

## HANDLING:

Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

08/18

## RELATED PRODUCTS:

GNF-5837 (**B1339**)

Altiratinib (**9563**)

GW-441756 (**B1147**)

LOXO-195 (**B2226**)

## USAGE:

**FOR RESEARCH USE ONLY! Not to be used in humans**